The promoter hypermethylation of Keap1 that can lead to reduction of Keap1 expression and Nrf2 accumulation in the nucleus has been identified in malignant glioma [47], lung [48, 49], prostate [38], colorectal [50], gastric [51] and breast cancers [52]. The gene discussed is NFE2L2; the disease is breast carcinoma.